All Updates

All Updates

icon
Filter
Partnerships
Syntekabio and POLARISqb sign MOU to develop AI and quantum-powered drugs
AI Drug Discovery
Aug 31, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Aug 31, 2023

Syntekabio and POLARISqb sign MOU to develop AI and quantum-powered drugs

Partnerships

  • South Korea-based AI drug development company Syntekabio has signed a Memorandum of Understanding (MOU) with quantum computing-based drug discovery platform POLARISqb to leverage AI and quantum technologies in developing treatments for various conditions and diseases.

  • The collaboration aims to combine POLARISqb’s Quantum-aided Drug Discovery (QuADD) platform and Syntekabio’s DeepMatcher Drug Candidate Service (DDC) to discover active compounds and offer novel molecular leads to customers.

  • Founded in 2009, Syntekabio utilizes its AI drug development platform, DeepMatcher, to automatically generate novel drug candidates by blending advanced drug development techniques with genomic big data technologies. Furthermore, Syntekabio is developing an antigen prediction technology, which can be applied in conjunction with therapeutic vaccines and cell therapy products, to predict antibody-based therapeutics in the near future.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.